These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 21906584)
1. Clinical consequences of analytical variance and calculation strategy in oral busulfan pharmacokinetics. Olson MT; Lombardi L; Clarke W Clin Chim Acta; 2011 Nov; 412(23-24):2316-21. PubMed ID: 21906584 [TBL] [Abstract][Full Text] [Related]
2. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Nguyen L; Leger F; Lennon S; Puozzo C Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611 [TBL] [Abstract][Full Text] [Related]
4. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834 [TBL] [Abstract][Full Text] [Related]
5. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy. Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495 [TBL] [Abstract][Full Text] [Related]
6. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584 [TBL] [Abstract][Full Text] [Related]
8. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167 [TBL] [Abstract][Full Text] [Related]
9. Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? Buffery PJ; Allen KM; Chin PK; Moore GA; Barclay ML; Begg EJ Ther Drug Monit; 2014 Feb; 36(1):86-92. PubMed ID: 24299921 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of oral busulfan in children. Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512 [TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M; Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300 [TBL] [Abstract][Full Text] [Related]
12. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374 [TBL] [Abstract][Full Text] [Related]
13. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Kletzel M; Jacobsohn D; Duerst R Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731 [TBL] [Abstract][Full Text] [Related]
16. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185 [TBL] [Abstract][Full Text] [Related]
17. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185 [TBL] [Abstract][Full Text] [Related]
18. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965 [TBL] [Abstract][Full Text] [Related]